130 results on '"Park, Kwon-Sik"'
Search Results
2. Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer
3. Regulation of UHRF1 acetylation by TIP60 is important for colon cancer cell proliferation
4. CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma
5. Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD+ regeneration in KRas-mutant lung adenocarcinoma
6. PCLAF-DREAM drives alveolar cell plasticity for lung regeneration.
7. Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
8. Robo1 loss has pleiotropic effects on postnatal development and survival
9. CRACD suppresses neuroendocrinal plasticity of lung adenocarcinoma
10. Data from Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
11. Supplementary_table_S5 from Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
12. Supplementary Figure S1-S17 from Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
13. Data from Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
14. Figures S1-S16 from Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
15. Tables S1-S5 from Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
16. Supplementary Data 2 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
17. Figures S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
18. Data from WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
19. Supplementary Data from WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
20. Supplementary Fig 4 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
21. Supplementary Data 1 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
22. Supplementary Figure from WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
23. Supplementary Fig 2 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
24. Supplementary Methods from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
25. Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
26. Supplementary Table from WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
27. Supplementary File S1 from Fragmentation of Small-Cell Lung Cancer Regulatory States in Heterotypic Microenvironments
28. Supplementary Data 3 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
29. Data from Fragmentation of Small-Cell Lung Cancer Regulatory States in Heterotypic Microenvironments
30. Supplementary Fig 3 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
31. Supplementary Fig 1 from FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
32. Supplementary Data from Fragmentation of Small-Cell Lung Cancer Regulatory States in Heterotypic Microenvironments
33. Data from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
34. Supplementary Figure 7 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
35. Supplementary Figure 6B from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
36. Supplementary Figure 5 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
37. Supplementary Figure Legends 1-8, Table 1, Methods from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
38. Supplementary Figure 1 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
39. Supplementary Figure 3 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
40. Supplementary Figure 4 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
41. Supplementary Figure 8 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
42. Supplementary Figure 2 from Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
43. BCAT1 inhibition affects CD8+T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis
44. CRACD loss promotes small cell lung cancer tumorigenesis via EZH2-mediated immune evasion
45. CRACD, a gatekeeper restricting proliferation, heterogeneity, and immune evasion of small cell lung cancer
46. PCLAF-DREAM Drives Alveolar Cell Plasticity for Lung Regeneration
47. WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
48. Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD+ regeneration in KRas-mutant lung adenocarcinoma
49. WNT5A-RHOA axis is a new vulnerability in small-cell lung cancer
50. KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.